Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide in multiple sclerosis
NCT02466074Phase 2Terminated
- Sponsor
- UTHealth Houston
- Start
- Aug 2016
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing Acetazolamide with Placebo -> Acetazolamide (2 arms). Primary endpoint: Percent Change in Global Cerebral Blood Flow at 24 weeks. Started Aug 2016; status: terminated.
02
Drugs
acetazolamide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02466074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02466074.